SCHEMBL5207809

SCHEMBL5207809

COC(=O)c1ccc(C(=O)Nc2ccc(Cl)cn2)c(NC(=O)c2ccc(N3CCCN(C)CC3)nc2)c1

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
F10 P00742 16/20 0.62
RAB9A P51151 1/20 0.52
WDR5 P61964 2/20 0.48
DYRK1A Q13627 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5206177 0.92 F10 (0.64) F10RAB9ADYRK1A
SCHEMBL5202404 0.89 F10 (0.57) F10
SCHEMBL14394521 0.88 F10 (0.81) F10
SCHEMBL5205708 0.87 F10 (0.48) F10
Hydrochloric Acid SCHEMBL5204818 0.86 F10 (0.80) F10
SCHEMBL5202433 0.85 F10 (0.71) F10RAB9A
SCHEMBL4848558 0.84 F10 (0.74) F10RAB9A
SCHEMBL5202028 0.82 F10 (0.72) F10RAB9A
SCHEMBL14591676 0.82 F10 (0.48) F10
SCHEMBL14591686 0.81 F10 (0.58) F10RAB9ADYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307444-B1 SUBSTITUTED HETEROCYCLIC AMIDES LILLY CO ELI (US) 2007-10-03 EP disclosed
US-7160878-B2 Substituted heterocyclic amides ELI LILLY AND COMPANY (US) 2007-01-09 US disclosed
US-7160878-B2 Substituted heterocyclic amides ELI LILLY AND COMPANY (US) 2007-01-09 US disclosed
US-7160878-B2 Substituted heterocyclic amides ELI LILLY AND COMPANY (US) 2007-01-09 US disclosed
US-20040097491-A1 Substituted heterocyclic amides HERRON DAVID KENT (US) 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097491-A1 Substituted heterocyclic amides F12, F11, F8 F10 11/4885RAB9A 1432/4885WDR5 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.